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ABSTRACT
Aggressive forms of breast cancer, such as Her2C and triple negative breast cancer (TNBC), are enriched in
breast cancer stem cells (BCSC) and have limited therapeutic options. BCSC represent a key cellular reservoir
for relapse, metastatic progression and therapeutic resistance. Their ability to resist common cytotoxic
therapies relies on different mechanisms, including improved detoxification. The cystine-glutamate antiporter
protein xCT (SLC7A11) regulates cystine intake, conversion to cysteine and subsequent glutathione synthesis,
protecting cells against oxidative and chemical insults. Our previous work showed that xCT is highly
expressed in tumorspheres derived from breast cancer cell lines and downregulation of xCT altered BCSC
function in vitro and inhibited pulmonary metastases in vivo. We further strengthened these observations by
developing a virus-like-particle (VLP; AX09-0M6) immunotherapy targeting the xCT protein. AX09-0M6 elicited
a strong antibody response against xCT including high levels of IgG2a antibody. IgG isolated from AX09-0M6
treated mice bound to tumorspheres, inhibited xCT function as assessed by reactive oxygen species
generation and decreased BCSC growth and self-renewal. To assess if AX09-0M6 impacts BCSC in vivo
seeding, Her2C TUBO-derived tumorspheres were injected into the tail vein of AX09-0M6 or control treated
female BALB/c mice. AX09-0M6 significantly inhibited formation of pulmonary nodules. To evaluate its ability
to impact metastases, AX09-0M6 was administered to mice with established subcutaneous 4T1 tumors. AX09-
0M6 administration significantly hampered tumor growth and development of pulmonary metastases. These
data show that a VLP-based immunization approach inhibits xCT activity, impacts BCSC biology and
significantly reduces metastatic progression in preclinical models.
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It is estimated that in 2017, 252,000 women will be diagnosed
with breast cancer in the United States including 30,000 new
cases of triple negative breast cancer (TNBC), a highly aggres-
sive form of breast cancer.1 According to the hierarchical can-
cer model, mammary tumors, as the majority of cancers, are
organized in a cellular hierarchy with cancer stem cells (CSC)
at the apex.2 CSC are often enriched in highly metastatic breast
cancers, including TNBC and Her2C breast cancer.3 CSC have
the unique biological properties necessary for maintenance and
spreading of the tumor, and through asymmetric division can
differentiate into cancer cells that compose the tumor bulk.4,5
Due to their resistance to traditional radiation and chemothera-
pies,6 CSC represent a reservoir for the relapse, metastatic
evolution and progression of the disease after treatment. There-
fore, successful eradication of CSC represents a major barrier
towards effective cancer treatments.
The ability of CSC to resist common cytotoxic therapies relies
on different mechanisms, including improved detoxification abil-
ity. The cystine-glutamate antiporter protein xCT (SLC7A11),
the light chain of the antiporter system xc
¡, regulates cystine
intake, conversion to cysteine and subsequent glutathione (GSH)
synthesis, protecting cells against oxidative and chemical
insults.7,8 xCT is a 12 multi-pass transmembrane protein, charac-
terized by 6 extracellular domains (named ECD1-6), in which the
N- and C-termini are located intracellularly.9 xCT expression is
low in normal cells and highly restricted to a few cell types (astro-
cytes, microglia and other subsets of myeloid cells),10,11 but ele-
vated levels of xCT protein are observed in a high percentage of
mammary tumors including TNBC.12 High levels of xCT mRNA
and protein correlate with significant reduction in distal metasta-
ses-free and overall survival.13,14 xCT expression is upregulated
in breast CSC (BCSC)15 and other solid tumor stem cells,16–21
and several studies show that xCT physically interacts with the
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well-known stem cell proteins, CD44 and MUC1.6,20–23 The fre-
quency of xCT expression on a variety of CSC suggests that ther-
apies targeting xCT may be effective in treating many tumors
with high stem cell frequencies including gastrointestinal23 and
pancreatic24 cancers.
Our published work established xCT as an immunotherapeu-
tic target for BCSC.12 Microarray analysis identified xCT as a
gene that was upregulated in BCSC and subsequent studies con-
firmed xCT upregulation in human and murine BCSC.12 Inhibi-
tion of xCT function resulted in a significant decrease of BCSC
viability, reduced self-renewal and altered cellular redox levels.
A direct role for xCT in breast cancer growth and metastasis
was shown by immunizing mice with a DNA-based vaccine
expressing the full-length xCT protein.12 Administration of the
xCT vaccine prior to or in mice with existing tumors resulted in
significantly decreased pulmonary metastases and tumors con-
taining significantly less BCSC compared to control animals. The
combination of xCT vaccination and chemotherapy synergisti-
cally reduced metastatic disease compared to mice that were
treated with either therapy alone.12 Similar results were observed
by inhibiting xCT function with the small molecule sulfasalazine
(SASP),6,7,25,26 a Food and Drug Administration (FDA)-
approved anti-inflammatory drug characterized by low specific-
ity for xCT, short bioavailability and numerous side effects.27,28
The mechanism of action for DNA vaccination usually acts
through cytotoxic CD8 T cell activation. However, there was
no T-cell response to the major xCT T-cell epitope in DNA
vaccinated mice, and immunization in B-cell deficient mice
showed inadequate therapeutic responses.12 IgG antibodies
isolated from the sera of vaccinated mice inhibited BCSC
function in vitro in a similar manner as siRNA and SASP
treatment, demonstrating that vaccine-induced xCT antibod-
ies represented the therapeutic effectors.12 However, antibody
titers achieved using the DNA vaccine were low, suggesting
that the development of new therapies generating a focused,
high titer antibody response would lead to greater inhibition
of metastatic progression.
Virus-like particle (VLP) vaccines generate strong immune
responses29 due to their optimal size, particulate nature, and
potent intrinsic adjuvant activity.30 Agilvax’s VLP technology is
derived from a family of single-stranded RNA bacteriophages,
including MS2, PP7, Qß, and AP205. To create a VLP that was
more thermodynamically stable and dramatically more tolerant
of foreign AB loop peptide insertions, Agilvax engineered a sin-
gle-chain dimer version of the MS2 coat protein. Resulting
VLPs are comprised of a single coat protein that self-assembles
into a 27 nm diameter icosahedral particle consisting of 90 coat
protein dimers. Our VLP technology allows for the precise con-
trol of epitope size, structure (loop/linear) and valency to opti-
mize immune responses for a specific antigen.31–34 Epitopes are
displayed in an ordered, geometric pattern on the surface of the
VLPs and elicit robust antibody responses, even against self-
antigens.35–37 In this paper, we produced and tested a novel
VLP-based immunotherapy (AX09-0M6) that displays the 6th
extracellular domain (ECD6) of human xCT in the AB surface
loop on the MS2 VLP. Dosing of BALB/c mice with AX09-0M6
generated high titer antibodies that bound to xCT expressing
BCSC and these antibodies inhibited BCSC function in vitro.
Mice immunized with AX09-0M6 had significantly less
pulmonary metastases compared to controls in syngeneic mod-
els of breast cancer.
Results
Construction of xCT VLPs
To construct a VLP-based immunotherapy targeting xCT, we
identified five (out of six) potential ECD from the human xCT
structure to display on the surface of our VLP technology
(Fig. 1A). The various ECD of human xCT were cloned into
the coat protein (CP) AB loop rather than in a linear display
point of our VLP to more closely mimic the native cellular
structure of the xCT domains. The VLPs were expressed in
E. coli, purified (Fig. 1B) and initial characterization showed
that VLPs displaying ECD1, ECD3 and ECD6 assembled prop-
erly. Based upon ECD6 full homology in human and mouse
xCT sequence, the VLP displaying the ECD6 peptide (AX09-
0M6) was used for the pre-clinical studies reported here.
AX09-0M6 administration induces a functional xCT
antibody response
To evaluate antibody responses, female BALB/c mice were
immunized two times in the absence of exogenous adjuvant
Figure 1. xCT structure and VLP production. (A) Human xCT contains six extracellu-
lar domains that range from 2 aa (ECD5) to 31 aa (ECD4) (NCBI Reference
Sequence: NP_055146.1). The human ECDs exhibit high homology to mouse with
ECD6 showing 100% identity. (B) Production of xCT VLPs. The single chain MS2
coat protein (CP) was synthesized to contain an individual xCT ECD displayed in
the AB loop domain to more closely mimic native xCT structure. Plasmids were
introduced into cells by transformation where MS2 CP self assembles into VLPs.
Bacteria were lysed and VLPs were purified from the soluble protein fraction. The
xCT VLPs differ from wild-type MS2 VLPs only in the xCT ECD peptide displayed in
the surface exposed AB loop.
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with AX09-0M6 or control MS2 wild-type (MS2 wt) and a pep-
tide ELISA was used to measure the end-point titer. Sera from
AX09-0M6 treated BALB/c mice were serially diluted and incu-
bated with xCT ECD6 peptide coated wells and specific anti-
body binding was analyzed by ELISA. AX09-0M6 generated
peptide antibody titers from 5 £ 102 to 1.4 £ 104 with an aver-
age of 3 £ 103 (Fig. 2A), whereas no detectable binding was
observed in mice treated with MS2 wt. Immune sera were also
analyzed for relative amounts of different IgG isotypes. AX09-
0M6 induced high levels of IgG2a compared to IgG1, indicative
of a Th1 biased antibody response (Fig. 2B). IgG2b levels
were also elevated compared to IgG1 (Fig. 2B), while little
detectable IgG3 was observed (data not shown).
To analyze the ability of AX09-0M6 induced antibodies to
bind BCSC, tumorspheres derived from TUBO (mouse
HER2C; Fig. 2C), 4T1 (mouse TNBC; Fig. 2D), HCC-1806
(human TNBC; Fig. 2E) and MDA-MB-231 (human TNBC;
Fig. 2F) cells were incubated with IgG purified from sera of
mice vaccinated with AX09-0M6 or MS2 wt and analyzed by
FACS. A commercial anti-xCT Ab was used as a control. IgG
from AX09-0M6 vaccinated mice bound to both mouse and
human xCTC BCSC, while no signal was observed with IgG
from MS2 wt treated mice.
These results were confirmed by the ability of IgG purified
from AX09-0M6-immunized mouse sera to stain tumorspheres
derived from TUBO (Fig. 3A), 4T1 (Fig. 3B), HCC-1806
(Fig. 3C) and MDA-MB-231 (Fig. 3D) cells, as shown by confo-
cal images (Fig. 3, on the left) and fluorescent signal quantifica-
tion graphs, calculated as integrated density normalized to
nuclei number (Fig. 3, on the right). No binding was observed
in cells incubated with purified IgG from MS2 wt treated mice.
Antibodies induced by AX09-0M6 inhibit BCSC function
To test the effect exerted by anti-xCT antibodies induced by
VLP vaccination on BCSC, tumorspheres generated from
TUBO cells were incubated for 5 days with IgG purified from
the sera of vaccinated mice or with the xCT inhibitor sulfasa-
lazine (SASP). As reported in Fig. 4A, IgG from MS2 wt
treated mice did not affect BCSC, while those purified from
AX09-0M6 vaccinated mice reduced the number (Fig. 4A,
panel i) and dimension of spheres (Fig. 4A, panel ii and Sup-
plementary Fig. 1A), exerting an effect comparable to SASP.
This reduced sphere-generation ability was accompanied by
both a decrease in the percentage of BCSC, evaluated as cells
positive for the Aldefluor reagent that measures aldehyde
dehydrogenase-1 activity (Fig. 4A, panel iii), and an increase
in Reactive Oxygen Species (ROS) content as compared with
MS2 wt (Fig. 4A, panel iv).
The ability of anti-xCT antibodies induced by VLP vaccina-
tion to inhibit BCSC was not restricted to the TUBO model, as
similar results were obtained in other murine (4T1; Fig. 4B and
Supplementary Figure 1B) and human (HCC-1806 and MDA-
MB-231, Fig. 4C, D and Supplementary Fig. 1C, D) TNBC cell
lines. These results suggest that AX09-0M6 elicits anti-xCT
antibodies affecting BCSC self-renewal ability.
ROS levels are regulated by xCT via production of GSH, and
inhibition of xCT function using a variety of approaches results
in an increase in intracellular ROS levels.12 To investigate if
AX09-0M6 elicits antibodies that inhibit xCT function, tumor-
spheres were incubated for 5 days with IgG purified from MS2
wt or AX09-0M6 vaccinated animals. As seen in Fig. 4 (panel
iv), IgG from AX09-0M6 mice resulted in a significant increase
in the intracellular ROS levels similar to SASP. In contrast,
there were no differences in ROS levels from tumorspheres
incubated with IgG from MS2 wt sera, suggesting that AX09-
0M6 elicits antibodies that bind to and inhibit xCT function.
AX09-0M6 treatment has limited or no effect on normal
tissues expressing xCT
Since xCT is expressed at low levels by mouse (but not human)
spleen myeloid cells,38 we analyzed the relative amount of these
cell populations in the spleen of vaccinated mice as compared
to untreated or MS2 wt treated mice. As shown in Fig. 5A,
AX09-0M6 did not induce any reduction in dendritic cells,
neutrophils, and macrophages. When xCTC cells were evalu-
ated, no significant alterations were found (Fig. 5B), but there
was a trend towards a reduction in xCTC neutrophils and mac-
rophages (Fig. 5B). In the case of macrophages, the reduction
was primarily found in the M1 and M0 subsets (Fig. 5C).
In the mouse, xCT is also expressed in the central nervous
system by astrocytes and microglia.10,11 In order to exclude
brain toxicity in vaccinated mice, we performed a histological
and immunohistochemical analysis of brains from AX09-0M6
vaccinated BALB/c mice whose sera endpoint titers are
reported in Fig. 2A. Haematoxylin and Eosin (H&E) staining
showed no significant morphological alterations and lesions,
which suggests that vaccination-induced toxicity was not pres-
ent. Slight lesions of uncertain meaning, artifacts or agonics,
and tiny lymphocytic infiltrates have been detected, but they
were distributed in all groups (untreated, MS2 wt and AX09-
0M6 treated; data not shown). Immunohistochemical analysis
with the F4/80 microglial marker did not reveal any alterations
and differences in the AX09-0M6 treated group versus the MS2
wt treated and untreated groups (Fig. 5D-F). Similarly, no sig-
nificant inflammatory cell infiltrates or any other abnormalities
were detected in H&E-stained sections of brains from outbred
CD-1 mice (data not shown) in which immunization with
AX09-0M6 generated very robust endpoint titers (Supplemen-
tary Fig. 2A). The lack of toxicity was also supported by
the absence of any detectable behavioural changes, such as
increased aggressiveness, narcolepsy or uncoordinated move-
ments, in living AX09-0M6 mice.
AX09-0M6 attenuates experimental metastases in vivo
affecting the immune infiltrate
To evaluate the ability of AX09-0M6 to inhibit CSC mediated
seeding and resuming growth at the metastatic site in vivo, we
used a well-characterized preventive mouse cancer model.12,39
Female BALB/c mice were vaccinated twice at two-week inter-
vals with MS2 wt or AX09-0M6. One week after final boost,
mice were injected intravenously (i.v.) with TUBO-derived
tumorspheres and the number of micrometastases was evalu-
ated histologically three weeks later. Mice treated with AX09-
0M6 had a significant decrease (»42%) in the number of
pulmonary metastases compared to control animals (Fig. 6A).
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Figure 2. AX09-0M6 induced strong antibody responses. (A) Peptide ELISA of sera from treated BALB/c mice were serially diluted and incubated with xCT ECD6 peptide
coated wells. End-point titers were determined by the highest dilution that was 2-fold over background. No titer was observed with control sera. Each dot represents an
individual animal treated with AX09-0M6 and results are from 3 independent experiments. (B) AX09-0M6 sera from panel A were analyzed for relative amounts of differ-
ent IgG isotypes. The relative ratio of each IgG subclass was calculated for each animal by taking the average OD450 value from a given IgG subclass (IgGx) divided by the
average OD450 from total IgG. (C-F) FACS analysis of tumorspheres derived from TUBO (C), 4T1 (D), HCC-1806 (E) or MDA-MB-231 (F) cells incubated with 50 mg/ml IgG
purified from sera of MS2 wt or AX09-0M6-vaccinated mice, or with a commercial anti-xCT Ab. Representative histograms are shown. Graphs show the mean § SEM of
the percentage of positive cells set on the base of FITC-conjugated secondary Ab staining and of mean fluorescence intensity from 3 independent experiments. , P <
0.05; , P < 0.01, , P < 0.001, Student’s t-test .
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To see if AX09-0M6 administration could alter the tumor
microenvironment, immune infiltrates in lungs were assessed
using FACS analysis. As shown in Fig. 6B, AX09-0M6 induced
a significant increase in lung infiltrating NK cells and a trend
showing an increase in T cells, while no difference in either gd
T cells and NKT cells were observed compared to untreated or
MS2 wt vaccinated mice. Of note, both MS2 wt and AX09-0M6
increased the proportion of CD8C T cells and decreased that of
CD4C T cells when compared to untreated mice (Fig. 6C),
suggesting that VLPs may influence the tumor microenviron-
ment independently of the expression of a specific peptide in
the CP AB loop. Although not significant, MS2 wt and, to a
greater extent, AX09-0M6, decreased the number of
Ly6GCLy6CC neutrophils and increased both the Ly6G¡Ly6CC
monocytes and F4/80C macrophages compared to untreated
animals (Fig. 6D).
The increased number of NK cells in the lungs of AX09-
0M6 treated mice and the fact that AX09-0M6 induces xCT
Figure 3. AX09-0M6-induced antibodies target tumorspheres. Representative immunofluorescence images of TUBO (A), 4T1 (B), HCC-1806 (C) and MDA-MB-231 (D)-
derived tumorspheres incubated with IgG (50 mg/ml) purified from sera of BALB/c mice vaccinated with MS2 wt or AX09-0M6. The specific signal (green) was detected
with an Alexa Fluor488-conjugated anti-mouse secondary antibody. Nuclei were counterstained with DAPI (blue). Magnification 40X, Scale bar, 40 mm , P < 0.01, Stu-
dent’s t-test.
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targeting antibodies mainly of the IgG2a subclass, were sug-
gestive of a possible role of antibody-dependent cellular
cytotoxicity (ADCC) in vaccine-mediated metastatic inhibi-
tion. To test this possibility, we performed an ADCC in
vitro assay by using xCTC 4T1 cells as targets incubated
with the sera (1:50 dilution) from mice treated with AX09-
0M6, MS2 wt or left untreated and autologous splenocytes
(SPC) as effectors. As shown in Fig. 6E, SPC in the pres-
ence of pooled sera from AX09-0M6 vaccinated mice medi-
ated higher ADCC at 200:1 and 100:1 effector/target ratios
than sera from MS2 wt treated (P D 0.0595 and P D
0.0468, respectively) or untreated control (P D 0.0297 and
P D 0.0033, respectively) mice.
AX09-0M6 slows in vivomammary tumor growth
and attenuates spontaneous metastases
To investigate if AX09-0M6 would affect tumor growth and
metastatic progression in mice with existing tumors, we used
the 4T1 syngeneic therapeutic model.40 Tumorspheres gener-
ated from 4T1 cells were administered subcutaneously (s.c.)
into the mammary fat pad. When the tumors were 1 – 1.5 mm
in diameter, mice were vaccinated with AX09-0M6 followed by
a boost 2 weeks later. As seen in Fig. 7A, the tumor growth rate
(as measured by tumor volume) was significantly slower in the
AX09-0M6 treated animals compared to controls. Forty
days after tumor challenge, animals were euthanized and the
Figure 4. Vaccine-induced antibodies target CSC and affect self-renewal and ROS flux. TUBO (A), 4T1 (B), HCC-1806 (C) and MDA-MB-231 (D)-derived tumorspheres were
incubated for 5 days with medium, IgG (50 mg/ml) purified from sera of BALB/c mice vaccinated with MS2 wt or AX09-0M6, or with SASP (50 mM). i) Sphere generating
ability reported as tumorsphere number/103 plated cells. ii) Sphere diameter measured with the AxioVision 4.8 software. FACS analysis of iii) Aldefluor positivity reported
as percentage of positive cells and of iv) ROS production, reported as DCF MFI. All graphs show mean § SEM from at least three independent experiments. , P < 0.05;
, P < 0.01, , P < 0.001, Student’s t-test.
e1408746-6 E. BOLLI ET AL.
number of micrometastases was measured. Similar to the pre-
ventative model, treatment with AX09-0M6 significantly inhib-
ited the number of spontaneous pulmonary metastases
compared to control animals (Fig. 7B), suggesting that AX09-
0M6 might represent a new immunotherapy option for breast
cancer patients.
Discussion
Our previous work showed that xCT is upregulated in
human and murine BCSC and established xCT as an immu-
notherapeutic target for BCSC.12 In this manuscript, we
show that an active immunization approach using a
VLP-based immunotherapy targeting xCT significantly
decreased lung metastases in a therapeutic model of aggres-
sive TNBC breast cancer. Moreover, this vaccination was
successful in decreasing HER2C BCSC seeding, thus reduc-
ing tumor growth at the metastatic site. In the therapeutic
setting, AX09-0M6 also decreased the primary tumor
growth rate (as assessed by tumor volume) in the xCT posi-
tive 4T1 TNBC model,40 suggesting that AX09-0M6 may
have additional activity in the 30% of TNBC patients whose
bulk tumor cells are also xCT positive.13,26
The mechanism of action for AX09-0M6 is mostly through
the generation of an oligoclonal xCT antibody response and
efficacy is therefore independent from MHC expression and
can target CSC that are known to downregulate the expression
of MHC class I molecules to escape cytotoxic T lymphocyte
attack.41,42 AX09-0M6 induced antibodies inhibited xCT func-
tion in vitro resulting in a significant decrease of BCSC viability,
reduced self-renewal and altered cellular redox levels, showing
that xCT is required for BCSC function rather than simply rep-
resenting a biomarker of BCSC. Therefore, AX09-0M6 treat-
ment (and other therapies inhibiting xCT function) should not
lead to cancer escape mutants via antigen loss mechanisms.43,44
Besides the direct effect of antibodies on xCT function, it
should be noted that AX09-0M6 induced a predominant IgG2a
antibody response, a subclass that has strongADCC and Comple-
ment Dependent Cytotoxicity (CDC) activity. Indeed, sera from
AX09-0M6 vaccinated mice was able to induce cytotoxicity
against xCTC tumor cells. Moreover, analysis of tumor infiltrating
lymphocytes (TILs) showed higher levels of NK cells in the meta-
static lungs from AX09-0M6 treated animals, supporting a possi-
ble role of ADCC in vaccine-mediated metastatic inhibition.
The increased T cell infiltration in metastatic lungs, even
though not statistically significant, is also promising and can be
justified by the antibody-mediated inhibition of xCT function.
Indeed, it has been shown that xCT inhibition results in a
decrease of b-catenin transcriptional activity,7 which inversely
correlates with CD8C T cell infiltration45 while it is associated
with infiltration of T regulatory cells and their survival.46
AX09-0M6 is initially being developed as an adjuvant ther-
apy for TNBC, due to the high frequency of xCT expressing
BCSC found in these tumors, the high rates of relapse and
metastatic progression and the lack of targeted therapies.
However, research suggests that AX09-0M6 may be of benefit
to patients with other indications. The xCT protein is
expressed in BCSC and differentiated breast cancer cells in a
subset of patients presenting with a variety of breast cancer
subtypes, suggesting that xCT positive patients who become
refractive to frontline, targeted breast cancer therapy may
benefit from AX09-0M6 treatment. Among the others, pan-
creatic,24 gastrointestinal,23 glioblastoma47 and colorectal20
Figure 5. No signs of toxicity in the spleen and brain of AX09-0M6 treated mice. (A-C) FACS analysis of SPC from mice left untreated (white bars) or vaccinated with MS2
wt (black bars) or AX09-0M6 (gray bars). A) Percentage § SEM of CD11cC dendritic cells, Ly6GCLy6CC neutrophils and F4/80C macrophages among the CD45C cell popu-
lation. (B) Percentage§ SEM of xCTC CD11cC dendritic cells, Ly6GCLy6CC neutrophils and F4/80Cmacrophages among the CD45C cell population. (C) Percentage§ SEM
of xCTC HLA class IIC M1, HLA class IIC CD206C M1/M2, CD206C M2 and HLA class II¡ CD206¡ M0 F4/80C macrophages among the CD45C cell population. (D-F) F40/80
immunohistochemical staining in brain from untreated (D), MS2 wt (E) and AX09-0M6 (F) representative mice; microglial cell processes are stained in brown. (20X, scale
bar 100 mm).
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CSC express xCT and inhibition of xCT functions in preclini-
cal models of these cancers using SASP showed reduced
metastases and tumor growth.
AX09-0M6 has potential as an add-on therapy for conven-
tional and emerging frontline therapies. Many chemotherapeu-
tic agents upregulate xCT protein in more differentiated cancer
cells, which conveys resistance to many of these thera-
pies.12,15,48,49 Therefore, AX09-0M6 inhibition of xCT function
in combination, or sequentially, with chemotherapy may elicit
clinical benefit by sensitizing bulk tumors to chemotherapeutic
agents as well as targeting BCSC. The use of blocking monoclo-
nal antibodies to the checkpoint inhibitor Programmed Death-
Ligand 1 molecule (PD-L1) is currently in trials for TNBC.50
PD-L1 is expressed on human CSC and a preliminary FACS
experiment shows that PD-L1 is also expressed on 4T1-derived
BCSC (data not shown). The combination of AX09-0M6 ther-
apy with PD-L1 blockade may be more effective in reducing
BCSC function while still blocking the PD1-PD-L1 axis in the
Figure 6. AX09-0M6 attenuates metastases in vivo affecting the immune infiltrate and induces antibodies stimulating ADCC. (A) Mice were treated with MS2 wt or AX09-
0M6 in the absence of exogenous adjuvant. One week after final administration, P2 tumorspheres derived from TUBO cells were injected into the tail vein of treated
mice. 20 days after cell challenge, the lungs were removed, sectioned and the number of micrometastases was determined. Each dot represents a single animal and is
the average number of lung metastases from at least 2 sections. Results shown are the aggregate from 3 independent experiments. , P D 0.0293; , P D 0.0025, Mann
Whitney test. (B-D) Cytofluorimetric analysis of immune infiltrates in lungs of mice left untreated (white bars) or vaccinated with MS2 wt (black bars) or AX09-0M6 (gray
bars). (B) Graph shows the percentage § SEM of CD45C cells expressing the markers of T (CD3CCD49b¡), NK (CD3¡CD49bC), gd T (CD3CgdC), and NKT (CD3CCD49bC)
cells. (C) Percentage § SEM of CD4C or CD8C cells among the CD45CCD3C T cell population. (D) Percentage § SEM of Ly6GCLy6CC neutrophils, Ly6G¡Ly6CC monocytic
MDSC and F4/80C macrophages among the CD45CCD11bC myeloid cell population. Three independent experiments were performed and a representative one is shown.
E) ADCC assay was performed using 4T1 target cells incubated with 1:50 pooled sera from vaccinated mice (AX09-0M6, gray bars; MS2 wt, black bars and untreated, white
bars) and SPC effector cells at different effector/target cells ratios (200:1, 100:1, and 50:1). Results shown are the mean§ SEM of the percentage of ADCC. , P< 0.05; , P
< 0.01, , P < 0.001, Student’s t-test.
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tumor bulk. Studies investigating combination therapies with
AX09-0M6 are being planned.
Targeting self-antigens can raise safety concerns about
effecting normal cells and the induction of autoimmune dis-
ease. The xCT protein is highly restricted to a few normal cell
types, mostly myeloid cells in the spleen and astrocytes and
microglia in the central nervous system. We have observed no
toxicity when inhibiting xCT function in vivo using AX09-0M6
and DNA-based vaccines. In particular, no inflammatory cell
infiltrates or any other abnormalities were detected in brains
from both BALB/c and CD-1 mice immunized with AX09-
0M6. We believe this result is particularly valuable for the clini-
cal development of AX09-0M6 because it shows that the vac-
cine generates very robust antibody response in both inbred
and outbred mice (e.g. representative of human diversity) with
apparently limited or no toxicity.
VLPs targeting both self-antigens and infectious agents
(including FDA approved VLP-based vaccines) have demon-
strated excellent safety profiles in the clinic. While VLPs elicit
high titer antibodies against self-antigens, these antibody
responses wane over time. Pharmacokinetic data in human clini-
cal trials performed by Cytos using a similar bacteriophage VLP
as AX09-0M6, showed antibody titers against self-antigens had
half-lives of »3 months, which is in stark contrast to long-lived
antibody responses using VLP-based vaccines targeting patho-
gens.51–53 There has been no evidence for antibody boosting by
tissue expression of the endogenous self-antigen in animal mod-
els, presumably because foreign T-cell helper responses are
required to boost antibody production. Therefore, the duration
and magnitude of xCT antibodies are controlled by AX09-0M6
dose and dosing schedule, reducing the possibility of autoimmune
disease. Also, the xCT octamer (amino acids 443–450) carried by
AX09-0M6 is smaller than effective T-cell epitopes, which nearly
eliminates the potential of inducing an autoreactive xCT T-cell
response. This apparent lack of a CTL response against xCT was
endorsed by the inability of SPC from AX09-0M6 vaccinated
mice to kill 4T1 cells in vitro and to upregulate CD107a/b expres-
sion after 6 days of co-culture with xCTC 4T1 cells (data not
shown). Nevertheless, the vaccine clearly elicits a T helper 1
response, as indicated by the production of IgG2a against xCT,
but this T cell response is against T cell epitopes provided by the
VLP proteins that act as carriers.52,54,55 The small size of the xCT
epitope carried by AX09-0M6, however, also increases the proba-
bility of homology to other proteins and possible off target affects.
Indeed, xCT is one member of a large, highly homologous family
of heterogeneous amino acid transporters,56 most of which are
widely expressed by normal tissues and/or have been reported to
be upregulated in a variety of tumors.57 We have blasted the
ECD6 peptide with the sequence of most members of the Hetero-
meric Aminoacid Transporters family, including LAT1,58 the
most highly homologous to xCT, showing that it is not shared.
Further protein homology and cellular localization bioinformatics
will be used to identify any other potential cross-reactive target.
Ultimately, a VLP-based immunotherapy with no toxicity has
a great potential to be used in amaintenance/neo-adjuvant setting
for TNBC before tumor recurrence/refractory. AX09-0M6 could
slow or stop the cancer’s return by blocking residual CSC that
represents a major barrier towards effective cancer treatments.
Materials and methods
Cell and tumorsphere generation
4T1 and HCC-1806 cells were grown in RPMI-1640 Medium
(Invitrogen, Corp.) supplemented with 10% heat-inactivated
Fetal Bovine Serum (FBS; Sigma-Aldrich). MDA-MB-231 cells
Figure 7. AX09-0M6 is efficacious in preventative and therapeutic models of aggressive breast cancer. (A) Passage 1 tumorspheres derived from 4T1 cells were injected
into the inguinal mammary fat pad. When the tumors reached 1 – 1.5 mm in diameter, mice were treated with MS2 wt and AX09-0M6, and boosted 14-days later. Primary
tumor diameters were measured at the indicated time-points and tumor volume was calculated. Results shown are the average tumor volume from two independent
experiments and the error bars represent the standard deviation of the mean. AX09-0M6 vs MS2 wt: , P < 0.05; , P < 0.005; Student’s t test. AX09-0M6 vs untreated:
P < 0.005 from week 26 to 33; P < 0.05 from week 35; Student’s t-test. (B) Mice from A were euthanized 40 days after tumor challenge and the number of micrometasta-
ses was enumerated. Each dot represents a single animal and is the average number of lung metastases from at least 2 sections. , PD 0.0126; , PD 0.0046, Mann Whit-
ney test. Results shown are the aggregate from 2 independent experiments.
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were grown in Dulbecco’s Modified Eagle Medium (DMEM,
Invitrogen Corp.) supplemented with 10% FBS. All cells were
purchased from ATCC (LGC Standards). TUBO cells59 were
cultured in DMEM supplemented with 20% FBS. Each culture
medium was supplemented with Penicillin (100 U/mL) and
Streptomycin (100 U/mL) (Sigma-Aldrich). Cells were cultured
at 37C in a 5% CO2 incubator and all cells were tested negative
for mycoplasma using polymerase chain reaction (PCR)
MycoAlert assay (Lonza). Passage 1 and passage 2
(P1 and P2) tumorspheres were generated as previously
described.39
Production and purification of VLPs
Production and purification of single-chain dimer versions of
MS2 bacteriophage VLPs were done as described.60 Briefly,
ECD6 peptide sequence (LYSDPFST) derived from the sixth
loop of xCT protein was inserted genetically into the AB loop
of MS2 CP through pDSP62 plasmid as previously described.32
Plasmids were electroporated into the E. coli, T7 expression
strain C41 (DE3) (Lucigen), grown to mid-log phase and VLP
expression was induced by the addition of IPTG (1 mM,
Sigma-Aldrich) overnight at » 30C. Bacteria pellets were lysed
in lysis buffer (50 mM Tris-HCl, pH 8.5, 100 mM NaCl, 10 mM
EDTA), sonicated and purified from bacterial debris by centri-
fugation. Bacterial DNA was removed by treating the superna-
tant with DNaseI (10 units/mL, 1 hour at 37C; Sigma-Aldrich)
and the VLPs were purified by size exclusion chromatography
(Sepharose CL-4B resin, Sigma-Aldrich). Buffer exchange
(Phosphate-buffered saline, PBS) and concentration of purified
VLPs was achieved using ultrafiltration (Amicon Ultrafiltration
device, 100Kd MWCO) and resulting VLP preparations were
quantitated by Bradford assay (BioRad). VLP purity was
assessed by agarose and SDS-PAGE gel electrophoresis.
Purification of IgG for in vitro assays
Female BALB/c mice were administered 10 mg of VLP without
exogenous adjuvant by intramuscular (i.m.) injection followed
by a single boost 28 days later. Two weeks after final boost,
blood was collected by cardiocentesis and immune sera were
isolated as previously described.61 Total IgG were purified from
sera using affinity chromatography (Protein A/G Plus Agarose,
Pierce) following manufacturer’s protocol. Eluted fractions
containing IgG as assessed by SDS-PAGE analysis were con-
centrated into PBS using ultrafiltration (Amicon Ultrafiltration
device, 10 Kd MWCO) and protein concentration was deter-
mined by Bradford assay using a mouse IgG standard curve
(BioRad). Purified IgG was aliquoted and stored at ¡20C.
Characterization of antibody responses
xCT specific antibody responses were evaluated by ELISA using
ECD6 peptide (synthesized with a CGG linker at the C-termi-
nus; GenScript) as coating antigen. Avidin (Pierce) prepared in
PBS pH 7.5 was added to wells of Immulon 2HB ELISA Plates
(Thermo Scientific) at 500 ng/well and incubated for 2 h at
37C. Following washing, SMPH (Succinimidyl 6-((beta-malei-
midopropionamido)hexanoate); Thermo Scientific) was added
to wells at 1 mg/well and incubated for 2 h at 37C. ECD6 pep-
tide was added at 1 mg/well and incubated overnight at 4C.
Plates were blocked with 0.5% milk in PBS at room tempera-
ture for 1 h, and 3-fold dilutions (starting at 1:500) of sera from
individual animals were added to each well and incubated for
2 h. Wells were probed with HRP-labeled goat anti-mouse IgG
(Invitrogen; 1:5000) for 1 h. The reaction was developed with
TMB Solution (30,30,50,50-Tetramethylbenzidine, Calbiochem)
for 1 h and the reaction was stopped using 1% HCl. ECD6 reac-
tivity was determined by measuring optical density (OD) at
450 nm. Wells with twice the OD450 value of background (sera
from MS2 wt mice) were considered positive and the highest
dilution with a positive value was considered the endpoint dilu-
tion titer.
To determine IgG subclass elicited by VLP administration,
ELISA plates were coated as above. Total IgG and each IgG
subclass were measured in triplicate from each animal using a
sera dilution of 1:500. Wells were probed with HRP-labeled
goat anti-mouse IgG, IgG1, IgG2a, and IgG2b (Invitrogen;
1:5000) for 1 h. Detection was as described above. Relative
ratio of each IgG subclass was calculated by taking the average
OD450 value from IgGx divided by the average OD450 from
total IgG.
Immune sera effect on tumorspheres
P1 tumorspheres were dissociated and cultured at a density of
6 £ 104 cells/ml in a 6-well dish in the absence or presence of
50 mg/ml of purified IgG or of 50 mM SASP (sulfasalazine;
Sigma-Aldrich). After 5 days P2 tumorspheres were imaged with
an ApoTome fluorescence microscope (Zeiss) and sphere diame-
ter measured with the AxioVision 4.8 software as described.62
Spheres were counted and reported as number of spheres gener-
ated for every 103 cells plated, then they were dissociated and
processed for FACS analysis of Aldefluor and ROS.
Immunofluorescence
P2 tumorspheres were cytospinned to glass slides, fixed in 4%
formalin solution and then blocked in 10% bovine serum albu-
min (BSA, Sigma-Aldrich). Slides were incubated with 100 mg/
ml of purified IgG or 1:10 dilution of sera from CD-1 mice for
one hour at room temperature, washed with PBS and incubated
with rabbit AlexaFluor488-anti-mouse (Life Technologies).63
Nuclei were stained with DAPI (Sigma-Aldrich). Images were
acquired with a Leica TCS-SP5 II confocal microscope and ana-
lyzed using LASAF software (Leica). Fluorescence was quanti-
tated using ImageJ and signal was calculated as integrated
density normalized to nuclei number.
In vivo treatments
Female 6- to 8-week-old BALB/c mice (Charles River Laborato-
ries Italia) were maintained at the Molecular Biotechnology Cen-
ter, University of Torino, and treated in accordance with the
University Ethical Committee and European guidelines under
Directive 2010/63. Vaccination, performed either before (preven-
tive model) or after tumor challenge (therapeutic model), con-
sisted of two i.m. injections at 2 week intervals. Each mouse
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received 5-10 mg of MS2 wt or AX09-0M6, formulated in PBS for
a total volume of 50 mL. In the preventive model, one week after
last vaccination 5 £ 104 tumorspheres derived from TUBO cells
were injected i.v.. Mice were sacrificed at 20 days after cell chal-
lenge.39 In the therapeutic model, 1 £ 104 P1 4T1 tumorsphere-
derived cells were injected s.c. and when the tumor reached a
mean diameter of 1-1.5 mm, mice were vaccinated as described
above. Tumors were then measured twice a week with calipers in
two perpendicular diameters. Tumor growth was reported as vol-
ume calculated as (p/6) £ A2 £ B,64 where A and B represent
the short and long diameters, respectively. Mice were euthanized
40 days after tumor cell challenge. At sacrifice, blood was col-
lected by cardiocentesis and sera were stored at ¡20C for use in
immunoassays. Lungs were removed, the right lung was fixed in
formaldehyde solution (4%), paraffin embedded, sectioned, and
Hematoxylin and Eosin (H&E) stained. Micrometastases were
counted with a Nikon SMZ1000 stereomicroscope and analyzed
using ImageJ software (U.S. National Institutes of Health).
FACS analysis
Tumorsphere derived cells were stained with Aldefluor kit (Stem
Cell Technologies) as reported.39 To measure intracellular ROS
content, cells were stained with 20,70-dihydrochlorofluorescein
diacetate (DHCF-DA, Sigma-Aldrich) as described.12 To quan-
tify anti-xCT antibody titers, 5 £ 105 tumorsphere-derived cells
were incubated for 30 min at 4C with 50 mg/mL of IgG purified
from sera of vaccinated mice. Cells were pre-treated with Fc
receptor (FcR) blocker (CD16/CD32; Becton Dickinson) for
5 min at 4C. After washes with PBS containing 2% BSA (Sigma-
Aldrich) and 0.1% sodium azide (NaN3; Sigma-Aldrich), cells
were incubated with a 1:50 dilution of a FITC-conjugated anti-
mouse IgG antibody (DakoCytomation) for 30 min at 4C.65
Rabbit anti-xCT Ab (Thermo Fisher Scientific) followed by
FITC-conjugated anti-rabbit IgG Ab (DakoCytomation) was
used as a positive control on cells fixed and permeabilized with
BD Cytofix/Cytoperm kit (Becton Dickinson). Washed cells
were then acquired on the BD FACSVerse and analyzed with BD
FACSuiteTM software (Becton Dickinson). The results were
expressed as percentage of positive cells and as mean fluores-
cence intensity (MFI).
For the analysis of immune infiltrates, lungs from vaccinated
mice were finely minced with scissors and then digested by
incubation with 1 mg/ml collagenase IV (Sigma Aldrich) in
RPMI-1640 (Life Technologies) at 37C for 1 h in an orbital
shaker. After washing in PBS supplemented with 2% FBS, the
cell suspension was incubated with a buffer for erythrocyte lysis
(155 mM NH4Cl, 15.8 mM Na2CO3, 1 mM EDTA, pH 7.3) for
10 minutes at R.T., then passed through a 70-mm pore cell
strainer, centrifuged at 1400 rpm for 10 min and re-suspended
in PBS, treated with Fc receptor blocker as described.66 Cells
were then stained with the following Abs: anti-mouse CD45
VioGreen, anti-mouse CD3 FITC, anti-mouse CD4 APC-
Vio770, anti-mouse CD8 VioBlue, anti-mouse gd PE/Vio770,
anti-mouse CD49b PE, anti-mouse F4/80 PE/Vio770, anti-
mouse CD11b FITC, anti-mouse Ly6G Vioblue, and anti-
mouse Ly6C APC/Vio770 (all from Miltenyi Biotec). For the
analysis of xCT expression on myeloid SPC, spleens from vacci-
nated mice were smashed on a 70-mm pore cell strainer,
erythrocytes were lysed, FcR blocker and cells were stained
with anti-mouse CD45 VioGreen, anti-mouse F4/80 PE/
Vio770, anti-mouse Ly6G Vioblue, anti-mouse Ly6C APC/
Vio770, anti-mouse class II HLA APC (Miltenyi Biotec) and
anti-mouse CD206 PE (eBioscience). After washing, cells were
fixed and permeabilized with BD Cytofix/Cytoperm kit and
stained with rabbit anti-xCT Ab followed by FITC-conjugated
anti-rabbit IgG Ab. Samples were acquired on a BD FACSVerse
and analyzed using the BD FACSuite software.
Antibody-dependent cell-mediated cytotoxicity (ADCC)
1 £ 104 4T1 target cells were labeled with 2 mM of carboxy-
fluorescein diacetate succinimidyl ester (CFSE; Molecular
Probes) following the manufacturer’s instructions. ADCC was
initiated by the addition of SPC from untreated BALB/c mice
as effector cells (200:1, 100:1, and 50:1 as the effector: target (E:
T) ratio) and sera from vaccinated mice at a 1:50 dilution. The
plate was incubated overnight at 378C, then cells were har-
vested, stained with 1mg/ml 7-Amino-Actinomycin D (7-AAD,
BD Bioscience), acquired on the BD FACSVerse and analyzed
by BD FACSuiteTM software (Becton Dickinson). Percent kill-
ing was obtained by back-gating on the CFSEC targets and
measuring the % of 7-AADC dead cells. % ADCC for each
serum sample was calculated with the formula [(dead targets in
sample (%) – spontaneously dead targets (%))/(dead target
maximum-spontaneously dead targets (%))] £ 100. Spontane-
ous release was obtained by incubating target cells in medium
with serum, whereas maximal release was obtained after treat-
ment with triton solution.
Histological and immunohistochemical analysis
Mice were killed by anaesthesia overdose, and explanted brains
were fixed in 4% formalin for 24 hours and then sliced in coro-
nal sections and processed for histology.67 Paraffin sections
were cut at 5 mm and stained with Haematoxylin and Eosin
(H&E) or with immunohistochemical antibodies. For the
immunohistochemical detection of microglial cells, non-spe-
cific immunoreactivity was blocked by incubation of the brain
sections with 5% goat serum and 3% milk. The slides were
incubated for 1 hour with a rat anti-mouse F4/80 primary anti-
body (Abcam, CI:A3-1). Biotinylated anti-rat secondary anti-
body (Dako) was used and the avidin-biotin-peroxidase
complex (ABC reaction, Vector Lab) was visualized with diami-
nobenzidine. (Thermo Scientific). Sections were counterstained
with haematoxylin before dehydration and mounting. Slides
were digitized with the Panoramic Desk scanner and subse-
quently evaluated by a pathologist with Panoramic Viewer
(both from 3D HISTECH).
Statistical analysis
Differences in sphere formation, protein expression, number of
infiltrating cells and proliferation index were evaluated by a
Student’s t-test. Differences in number of metastases were eval-
uated by a non-parametric Mann Whitney test. Data are shown
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